Literature DB >> 2960621

Pneumocystis carinii pneumonia: a lethal complication of "pulse" methylprednisolone therapy.

G A Kozeny1, J P Quinn, V K Bansal, L L Vertuno, E Hano.   

Abstract

A previously healthy, HIV-negative, 67-year-old man developed rapidly progressive glomerulonephritis. Following "pulse" methylprednisolone therapy he developed Pneumocystis carinii pneumonia. This complication should be recognized as a potential hazard of "pulse" steroid therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2960621

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  5 in total

1.  Hepatic immunosuppressive effects of systemically administered novel dextran-methylprednisolone prodrugs with peptide linkers in rats.

Authors:  Imam H Shaik; Hitesh K Agarwal; Keykavous Parang; Reza Mehvar
Journal:  J Pharm Sci       Date:  2012-07-24       Impact factor: 3.534

2.  Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents.

Authors:  S A Mendoza; V M Reznik; W R Griswold; A M Krensky; P D Yorgin; B M Tune
Journal:  Pediatr Nephrol       Date:  1990-07       Impact factor: 3.714

3.  Plasma pharmacokinetics and tissue disposition of novel dextran-methylprednisolone conjugates with peptide linkers in rats.

Authors:  Suman Penugonda; Hitesh K Agarwal; Keykavous Parang; Reza Mehvar
Journal:  J Pharm Sci       Date:  2010-03       Impact factor: 3.534

4.  Attenuation of acute rejection in a rat liver transplantation model by a liver-targeted dextran prodrug of methylprednisolone.

Authors:  Anjaneya P Chimalakonda; Donald L Montgomery; Jon A Weidanz; Imam H Shaik; Justin H Nguyen; John J Lemasters; Eiji Kobayashi; Reza Mehvar
Journal:  Transplantation       Date:  2006-03-15       Impact factor: 4.939

5.  Fatal Pneumocystis pneumonia in a child treated for focal segmental glomerulosclerosis.

Authors:  J L Murphy; H L Kano; P J Chenaille; S P Makker
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.